These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 20608882

  • 1. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States.
    Angalakuditi M, Edgell E, Beardsworth A, Buysman E, Bancroft T.
    J Med Econ; 2010; 13(3):393-402. PubMed ID: 20608882
    [Abstract] [Full Text] [Related]

  • 2. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.
    Copher R, Cerulli A, Watkins A, Laura Monsalvo M.
    J Med Econ; 2012; 15(5):947-55. PubMed ID: 22554140
    [Abstract] [Full Text] [Related]

  • 3. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.
    Douwes JM, Roofthooft MT, Van Loon RL, Ploegstra MJ, Bartelds B, Hillege HL, Berger RM.
    Heart; 2014 Feb; 100(3):224-30. PubMed ID: 24390161
    [Abstract] [Full Text] [Related]

  • 4. Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study.
    Berger A, Edelsberg J, Teal S, Mychaskiw MA, Oster G.
    BMC Pulm Med; 2012 Dec 11; 12():75. PubMed ID: 23231890
    [Abstract] [Full Text] [Related]

  • 5. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D.
    Health Technol Assess; 2009 Oct 11; 13(49):1-320. PubMed ID: 19863849
    [Abstract] [Full Text] [Related]

  • 6. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G, Mehta S.
    Appl Health Econ Health Policy; 2009 Oct 11; 7(1):43-59. PubMed ID: 19558194
    [Abstract] [Full Text] [Related]

  • 7. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K, Gilbert N, Mebus S, Miera O, Fehske W, Uhlemann F, Mühler EG, Ewert P, Lange PE, Berger F, Schulze-Neick I.
    Eur J Clin Invest; 2006 Sep 11; 36 Suppl 3():32-8. PubMed ID: 16919008
    [Abstract] [Full Text] [Related]

  • 8. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.
    J Am Coll Cardiol; 2010 May 04; 55(18):1915-22. PubMed ID: 20430262
    [Abstract] [Full Text] [Related]

  • 9. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.
    J Heart Lung Transplant; 2007 Apr 04; 26(4):363-9. PubMed ID: 17403478
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The cost to managed care of managing pulmonary hypertension.
    Said Q, Martin BC, Joish VN, Kreilick C, Mathai SC.
    J Med Econ; 2012 Apr 04; 15(3):500-8. PubMed ID: 22313330
    [Abstract] [Full Text] [Related]

  • 12. Low-dose oral sildenafil for patients with pulmonary hypertension: a cost-effective solution in countries with limited resources.
    Vida VL, Gaitan G, Quezada E, Barnoya J, Castañeda AR.
    Cardiol Young; 2007 Feb 04; 17(1):72-7. PubMed ID: 17184573
    [Abstract] [Full Text] [Related]

  • 13. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study.
    Gruenig E, Michelakis E, Vachiéry JL, Vizza CD, Meyer FJ, Doelberg M, Bach D, Dingemanse J, Galiè N.
    J Clin Pharmacol; 2009 Nov 04; 49(11):1343-52. PubMed ID: 19755415
    [Abstract] [Full Text] [Related]

  • 14. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
    D'Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, Correra A, Scognamiglio G, Russo MG, Calabrò R.
    Int J Cardiol; 2012 Mar 22; 155(3):378-82. PubMed ID: 21081251
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM, Jabbour A, Weintraub R, Brown K, Hayward CS, Macdonald PS.
    J Heart Lung Transplant; 2007 Nov 22; 26(11):1079-83. PubMed ID: 18022071
    [Abstract] [Full Text] [Related]

  • 16. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy.
    Jacobs W, Boonstra A, Marcus JT, Postmus PE, Vonk-Noordegraaf A.
    J Heart Lung Transplant; 2009 Mar 22; 28(3):280-4. PubMed ID: 19285621
    [Abstract] [Full Text] [Related]

  • 17. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
    Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL.
    Circulation; 2003 Oct 28; 108(17):2066-9. PubMed ID: 14568893
    [Abstract] [Full Text] [Related]

  • 18. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.
    Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.
    Appl Health Econ Health Policy; 2011 Sep 01; 9(5):293-303. PubMed ID: 21875160
    [Abstract] [Full Text] [Related]

  • 19. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.
    Garris C, Jhingran P, Bass D, Engel-Nitz NM, Riedel A, Dennis G.
    J Med Econ; 2013 Sep 01; 16(5):667-77. PubMed ID: 23425294
    [Abstract] [Full Text] [Related]

  • 20. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.
    Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR.
    Br J Clin Pharmacol; 2005 Jul 01; 60(1):107-12. PubMed ID: 15963102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.